Riskpilot← Back to searchSign inGet full accessPHARMA 2100 ApS
APSBankruptCVR 26382785Dronning Ingeborgs Vej 9Industriel design og produktdesign · NACE 741010Est. 2002— employees
Revenue 2017
DKK 0
EBITDA margin
—
Equity ratio
100.0%
Financial strength
Net profit 2017
DKK -20K
| Revenue | DKK 0 | — |
| EBITDA | DKK -20K | — |
| Net profit | DKK -20K | — |
| Total assets | DKK 29K | -41% |
| Equity | DKK 29K | -41% |
| Employees | — | — |
Legal name
PHARMA 2100 ApS
CVR number
26382785
Legal form
Anpartsselskab
NACE code
741010 · Industriel design og produktdesign
Founded
1. januar 2002
Share capital
DKK 50.000
Employees
—
VAT registered
No
Audit selected
No
Last report
2017-06-30
Financial year
January – December
Signatory rights
Virksomheden tegnes af en likvidator
Address
Dronning Ingeborgs Vej 9
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | -2 | 0 | 0 |
| Staff expenses | -50 | -25 | -0 | -0 | -0 | -0 |
| EBITDA | -50 | -25 | -5 | -2 | 0 | -20 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -50 | -25 | -5 | -2 | 0 | -20 |
| Net financials | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -50 | -25 | -5 | -2 | 0 | -20 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -50 | -25 | -5 | -2 | 0 | -20 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
|---|---|---|---|---|---|---|
| Total assets | 133 | 83 | 52 | 50 | 50 | 29 |
| Equity | 83 | 57 | 52 | 50 | 50 | 29 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 50 | 25 | 0 | 0 | 0 | 0 |
| Total debt | 50 | 25 | 0 | 0 | 0 | 0 |
EBITDA margin
-2045500.0%
This company
15.8%
Market median
-12946303% vs market
20122017
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
20122017
Return on equity
-69.6%
This company
18.4%
Market median
-478% vs market
20122017
Net profit margin
-2045500.0%
This company
8.1%
Market median
-25253186% vs market
20122017
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122017
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20122017
- Annual report 2017Filed via CVR / Virk · Period 2016-07-01 – 2017-06-30
- Annual report 2016Filed via CVR / Virk · Period 2015-07-01 – 2016-06-30
- Annual report 2015Filed via CVR / Virk · Period 2014-07-01 – 2015-06-30
- Annual report 2014Filed via CVR / Virk · Period 2013-07-01 – 2014-06-30
- Annual report 2013Filed via CVR / Virk · Period 2012-07-01 – 2013-06-30
- Annual report 2012Filed via CVR / Virk · Period 2011-07-01 – 2012-06-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
SS Management | Management | 2002 | — | — |
SL Chief Executive Officer | Chief Executive Officer | 2005 | — | — |
HU Audit | Audit | 2002 | — | — |
RS Management | Management | 2002 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2004 | — | — | |
| Chairman | 2014 | — | — | |
| Board of Directors | 2004 | — | — | |
| Chairman | 2010 | — | — | |
| Chairman | 2011 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of PHARMA 2100 ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Steen Schierbeck | Management | 0 companies |
| Sven Lange | Chief Executive Officer | 0 companies |
| Henrik Ulvsgaard | Audit | 0 companies |
| René Spurre | Management | 0 companies |
| Bent Holmegaard | Chairman | 0 companies |
| Bella da Silva Buxbom | Chairman | 0 companies |
| Ole Bitsch-Jensen | Board of Directors | 0 companies |
| Niels Meidahl | Chairman | 0 companies |
| Jens Meidahl | Chairman | 0 companies |